Clinical Cardiology Alert – January 1, 2003
January 1, 2003
View Archives Issues
-
Late-Breaking Trial
The following reports from the annual scientific sessions of the American Heart Association (AHA) meeting held November 17-20, 2002, in Chicago were obtained by handwritten notes, discussions with investigators, and news reports. -
CREDO
The 12-month results of CREDO (clopidogrel for the Reduction of Events During Observation) were presented at AHA to coincide with the publication of this important clinical trial in the November 20, 2002, issue of JAMA. -
SAPPHIRE
Carotid artery stenting is an attractive concept for the treatment of patients with significant carotid stenoses who were at higher risk for carotid endarterectomy, but stroke rates in initial studies were unacceptably high. -
PROSPER
The pravastatin in elderly individuals at risk of vascular disease (PROSPER) trial is a study of statin therapy in high-risk elderly individuals. PROSPER tested the hypothesis that the benefits of statin therapy on cardiovascular disease, stroke, and cognitive decline would be seen in the elderly, which had not yet been rigorously investigated with respect to LDL lowering with a statin. -
Response to Adenosine in Atrial Tachycardia
Iwai and colleagues evaluated the effects of adenosine in 42 patients who underwent an electrophysiologic study and radiofrequency ablation for recurrent atrial tachycardias. -
Ejection Fraction vs Inducible VT for Predicting Morbid Events
The multicenter, unsustained tachycardia trial (MUSTT) was a randomized clinical trial designed to test whether antiarrhythmic therapy guided by electrophysiologic testing would reduce arrhythmic death and total mortality in high-risk patients. -
Pharmacology Watch: FDA Approves Claritin For OTC Use For Seasonal Rhinitis
After years of legal wrangling, the FDA has approved loratadine (Claritin, Schering-Plough) as an over-the-counter (OTC) product for the treatment of seasonal rhinitis. -
Clinical Briefs in Primary Care Supplement